Orris

Tramadol

Reading File
Finding Sources
Searching PubMed

tramadol pharmacology mechanism opioid

Reading File
Reading File
Reading File

Tramadol

Mechanism of Action

Tramadol is a centrally acting analgesic with a dual mechanism:
  1. Weak mu-opioid receptor agonism - its affinity for the mu receptor is only 1/6000 that of morphine. However, its active metabolite O-desmethyltramadol (M1), formed via CYP2D6, is 2-4x more potent than the parent drug and carries much of the analgesic effect.
  2. Monoamine reuptake inhibition - inhibits reuptake of both serotonin (5-HT) and norepinephrine (NE), contributing to descending pain modulation.
The drug is supplied as a racemate; the (+) enantiomer has higher mu-receptor affinity and inhibits serotonin reuptake, while the (-) enantiomer is more active on NE reuptake and also stimulates alpha-2 adrenergic receptors. This synergy makes the racemate more effective than either enantiomer alone.
  • Goodman & Gilman's Pharmacological Basis of Therapeutics
  • Lippincott Illustrated Reviews: Pharmacology

Pharmacokinetics

ParameterDetail
Oral bioavailability68% (single dose)
MetabolismExtensive hepatic via CYP2D6 (active metabolite M1) and CYP3A4, CYP2B6
Elimination t1/2~6 h (tramadol), ~7.5 h (M1)
Onset of analgesia~1 hour (oral)
Peak effect2-3 hours
Duration~6 hours
ExcretionRenal (conjugated metabolites)
CYP2D6 pharmacogenomics matter significantly: Ultra-rapid metabolizers (UMs) can convert tramadol to M1 very quickly, raising toxicity risk. Poor metabolizers (PMs) get less analgesia. CPIC guidelines recommend against tramadol in CYP2D6 UMs and PMs.

Clinical Uses

  • Mild-to-moderate pain: as effective as morphine
  • Severe or chronic pain: less effective than morphine
  • Labor pain: comparable to meperidine, with less neonatal respiratory depression
  • Available as immediate-release, extended-release, and in fixed-dose combination with acetaminophen

Adverse Effects

EffectNotes
Nausea, vomitingVery common
Dizziness, headacheCommon
Sedation, dry mouthCommon
SeizuresCan occur even at therapeutic doses; risk higher with predisposing factors
Serotonin syndromeRisk with SSRIs, MAOIs, TCAs, and other serotonergic drugs
Respiratory depressionLess than equianalgesic morphine; naloxone can partially reverse it
ConstipationLess than with codeine
HypoglycemiaHigher risk vs. codeine, especially in the first 30 days of use
Dependence/withdrawalOccurs with chronic use; must taper before discontinuing

Overdose / Toxicity

  • Features: lethargy, nausea, tachycardia, seizures
  • At doses >500 mg: coma, hypertension, respiratory depression, apnea
  • Serotonin syndrome features can appear even in isolated tramadol overdose
  • Naloxone only partially reverses tramadol toxicity - it does not prevent seizures and may actually increase seizure risk
  • Tramadol-induced seizures are usually single and typically self-limited; anticonvulsants generally not needed
  • Tintinalli's Emergency Medicine

Key Drug Interactions

  • MAO inhibitors - contraindicated (seizure and serotonin syndrome risk)
  • SSRIs / SNRIs / TCAs - serotonin syndrome; also lowers seizure threshold
  • CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) - reduce M1 formation, reduce analgesia
  • CYP3A4 inducers (e.g., rifampicin, carbamazepine) - increase tramadol metabolism
  • CNS depressants - additive sedation and respiratory depression

Special Considerations

  • Abuse potential: Despite its weak opioid activity, tramadol should not be considered a non-addictive alternative to opioids - misuse and substance use disorder are documented.
  • Pediatrics: Contraindicated in children under 12 (and under 18 after certain surgeries like tonsillectomy) due to CYP2D6 variability and respiratory depression risk.
  • Renal/hepatic impairment: Reduced clearance - dose reduction needed; accumulation of M1 raises toxicity risk.
  • Pregnancy/lactation: Neonatal opioid withdrawal syndrome possible; excreted in breast milk.
Recent evidence note (2026): A 2026 systematic review [PMID 39965561] documents a range of psychological side effects from tramadol case reports, including depression, psychosis, and cognitive changes - reinforcing that its CNS effects extend well beyond analgesia.

Tramadol-serotonin syndrome risk: SSRIs and other drug interactions

Finding Sources
Searching PubMed

tramadol serotonin syndrome drug interactions

Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Here is a thorough breakdown of the tramadol-serotonin syndrome risk, drug interactions, clinical features, and management.

Tramadol and Serotonin Syndrome

Why Tramadol Is a Serotonin Syndrome Risk

Tramadol has a two-pronged serotonergic mechanism:
  1. Inhibits serotonin (5-HT) reuptake - its (+) enantiomer is the active component here
  2. Acts as a serotonin releaser (similar to venlafaxine) - increases synaptic 5-HT by promoting release, not just blocking reuptake
This means tramadol adds serotonergic load both by blocking clearance and by increasing release. Any other serotonergic drug on top creates a compounding effect. Importantly, serotonin syndrome can occur even with tramadol monotherapy at excessive doses, and rarely at therapeutic doses in susceptible individuals.
  • Kaplan and Sadock's Synopsis of Psychiatry; Goldman-Cecil Medicine

Drug Interactions by Category

1. SSRIs - Most Common Clinical Combination

SSRICYP2D6 InhibitionTramadol Interaction Risk
FluoxetinePotent inhibitorRaises tramadol plasma levels + additive serotonin
ParoxetinePotent inhibitor (strongest)Highest risk - documented serotonin syndrome in elderly
SertralineWeak inhibitorLower interaction risk than fluoxetine/paroxetine, but serotonin syndrome still reported
FluvoxamineCYP3A4 inhibitorRaises tramadol levels via CYP3A4; additive serotonin risk
Citalopram / EscitalopramMinimal CYP2D6 effectLowest pharmacokinetic interaction, but serotonergic risk still present
The dual hazard with paroxetine and fluoxetine: They both raise tramadol plasma concentrations (by blocking its CYP2D6 metabolism) AND add serotonergic burden directly. This is a pharmacokinetic + pharmacodynamic double hit.
  • Kaplan and Sadock's Synopsis of Psychiatry

2. MAO Inhibitors - Most Dangerous Combination

  • Contraindicated. MAOIs block breakdown of serotonin (via MAO-A), causing massive 5-HT accumulation when combined with tramadol's release/reuptake inhibition.
  • Can precipitate severe, life-threatening serotonin syndrome - hyperthermia >38.5°C, rigidity, increasing CO2 are markers of imminent death.
  • Applies to: phenelzine, tranylcypromine, isocarboxazid, and also linezolid (antibiotic with MAOI activity) and methylene blue.
  • MAO-B inhibitors (selegiline, rasagiline) used in Parkinson's disease also pose risk.
  • Goldman-Cecil Medicine; Tintinalli's Emergency Medicine

3. SNRIs

  • Venlafaxine, duloxetine, desvenlafaxine - all inhibit 5-HT reuptake, directly compounding tramadol's effect.

4. TCAs (Tricyclic Antidepressants)

  • Inhibit 5-HT and NE reuptake; many are also substrates/inhibitors of CYP2D6.
  • Coadministration with tramadol raises both serotonin syndrome and seizure risk.

5. Triptans (e.g., Sumatriptan)

  • Act as 5-HT1B/1D agonists; combination with tramadol can produce serotonin syndrome, though risk is debated.

6. Other Serotonergic Agents

  • Dextromethorphan (cough suppressants) - serotonin syndrome reported with tramadol + DXM
  • St. John's Wort (herbal) - hypericum inhibits 5-HT reuptake; often overlooked in drug histories
  • Antipsychotics (e.g., quetiapine) - partial 5-HT2A activity
  • Anticonvulsants with serotonergic properties (e.g., valproate, carbamazepine)
  • Antiparkinsonian agents (e.g., L-DOPA, bromocriptine)
  • MDMA / ecstasy - releases massive amounts of serotonin; fatal combinations reported with MAOIs

7. Bupropion - Special Note

  • Not directly serotonergic, but lowers seizure threshold significantly. Combined with tramadol's own pro-convulsant effect, the risk of seizure is substantially increased.
  • Kaplan and Sadock's Synopsis of Psychiatry

Clinical Features of Serotonin Syndrome

The classic triad (any combination can be present - severity is a spectrum):
DomainFeatures
Neuromuscular hyperactivityTremor, clonus (especially lower extremities/ankles), myoclonus, hyperreflexia, pyramidal rigidity
Autonomic hyperactivityDiaphoresis, fever, tachycardia, tachypnea, hypertension
Mental status changesAgitation, anxiety, confusion, delirium
GI symptomsNausea, vomiting, diarrhea
Onset is typically within hours of a new serotonergic agent or overdose. Clonus - particularly inducible ankle clonus - is a very specific sign.
Severity markers indicating life-threatening course: fever >38.5°C, rigidity, rising CO2 (respiratory failure), rhabdomyolysis, hyperkalemia.
  • Rosen's Emergency Medicine; Goldman-Cecil Medicine

Diagnosis: Hunter Criteria

In the setting of exposure to a known serotonergic agent, serotonin syndrome is diagnosed if any one of the following is present:
  1. Spontaneous clonus
  2. Inducible clonus + agitation or diaphoresis
  3. Ocular clonus + agitation or diaphoresis
  4. Tremor + hyperreflexia
  5. Hypertonic + temperature >38°C + ocular or inducible clonus
The Hunter criteria are more sensitive and have fewer false positives than the older Sternbach criteria.
  • Rosen's Emergency Medicine
Note: No lab test confirms serotonin syndrome. Check CK, electrolytes, and creatinine to screen for rhabdomyolysis and hyperkalemia when neuromuscular hyperactivity is prominent.

Differential Diagnosis

ConditionDistinguishing Features
NMSHistory of antipsychotic; slower onset (days); bradyreflexia (not hyperreflexia); "lead-pipe" rigidity
Malignant hyperthermiaTriggered by inhalational anesthetics/succinylcholine; elevated CK, metabolic acidosis
Anticholinergic toxicityDry skin/mucous membranes; urinary retention; absent bowel sounds; no clonus
Sympathomimetic toxicityStimulant history; diaphoresis but typically no clonus

Management

SeverityTreatment
All casesStop ALL serotonergic agents immediately
MildDiscontinuation + observation; low-dose benzodiazepines (e.g., diazepam 5-10 mg IV) for rigidity/agitation
Moderate-severeLarge-dose benzodiazepines (diazepam 10-20 mg IV, titrated in 10 mg aliquots); IV fluids
AdjunctCyproheptadine (5-HT2A antagonist) 12 mg oral single dose for severe/refractory cases - no RCT evidence but widely used; do NOT give if anticholinergic toxicity is on the differential
Hyperthermia not responding to sedationNeuromuscular blockade (rocuronium) + rapid sequence intubation; do NOT use succinylcholine if hyperkalemia is suspected from rhabdomyolysis
AvoidNaloxone is not effective for serotonin syndrome; antipyretics are not effective (fever is from muscle activity, not hypothalamic resetting)
  • Rosen's Emergency Medicine

Summary of Key Clinical Pearls

  • Paroxetine + tramadol is the highest-risk SSRI combination due to dual CYP2D6 inhibition + serotonin burden.
  • MAOIs + tramadol = contraindicated, potentially fatal.
  • Serotonin syndrome can occur with tramadol alone at high doses - no second drug required.
  • Naloxone does not treat serotonin syndrome and will not reverse this aspect of tramadol toxicity.
  • Clonus (especially ankle clonus) is the most specific neuromuscular sign - look for it actively.
  • Symptoms resolve within 24 hours with appropriate treatment in most cases; severe cases may persist for days.
This is a shared conversation. Sign in to Orris to start your own chat.